The Influence of Liraglutide for Heart Failure: A Meta-Analysis of Randomized Controlled Trials.
CONCLUSIONS: Liraglutide treatment has an important ability to reduce NT-proBNP and improve 6MWT for heart failure, but shows no important influence on LVEF, LVEDV, LVESV, hospitalization for heart failure, major adverse cardiovascular events, and cardiac death.
PMID: 31895026 [PubMed - in process]
Source: The Heart Surgery Forum - Category: Cardiovascular & Thoracic Surgery Authors: Zhang Y, Chen Q, Huang G, Wang L Tags: Heart Surg Forum Source Type: research
More News: Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Databases & Libraries | Heart | Heart Failure | Science | Victoza